

ANG1005: KOL Responses

KOL interviews support survey findings that ANG1005's product profile is compelling and that it has the potential to serve two markets with significant unmet need. The LRP-1 platform is universally acknowledged as being its most innovative attribute. MDs respond favorably to paclitaxel as the API.

